CD47 and cancer: Cancer cells exploit this negative regulatory mechanism by overexpressing CD47 on their surface to escape immune surveillance and blockade of SIRPα/CD47 interaction is reported to enhance anti-tumor ADCP and ADCC [36,38,39].